The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
The company has received a certificate of Good Manufacturing Practice compliance from the Medicines & Healthcare products Regulatory Agency (MHRA) UK
The government has taken all the effective measures to make healthcare affordable
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020
Subscribe To Our Newsletter & Stay Updated
